ライフサイエンスコーパス: interleukin-1

1 t production of the proinflammatory cytokine interleukin-1.

2 ory cytokines like tumor necrosis factor and interleukin-1.

3 nced by decreasing tumor necrosis factor and interleukin 1 alpha/beta mRNA levels.

4 n-glucose deprivation (OGD), reperfusion and interleukin-1 alpha (IL-1alpha) stimulate brain cells to

5 Interleukin-1 alpha (IL-1alpha) was increased in broncho

6 y cytokines, including TNF-alpha, IL-1alpha (Interleukin-1 alpha), RANTES (regulated on activation, n

7 se is driven by the proinflammatory cytokine interleukin-1 and is known to exacerbate resulting injur

8 y the much lower expression of receptors for interleukin-1 and TGFbeta, downstream protumor factors,

9 ession of proinflammatory cytokines (such as interleukin-1 and tumor necrosis factor-alpha) and chemo

10 ide primarily protects mice by repressing an interleukin-1- and 12/15-lipoxygenase-dependent neutroph

11 periodic syndromes respond to treatment with interleukin-1 antagonists, and single case reports of Sc

12 mofetil, and more children with JIA received interleukin-1 antagonists.

13 whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin

14 Here we tested polymorphisms of interleukin 1 beta (IL1B) and interleukin 1 receptor ant

15 endently in human astrocytes by the cytokine interleukin 1 beta (IL1B), and inactivation of Vegfa in

16 patients with high grade hepatic steatosis, Interleukin 1 beta encoding gene with anorexigenic funct

17 data on the association between SNPs in the interleukin 1 beta gene (IL1B) and colorectal cancer (CR

18 lation of the neuroimmunomodulating cytokine interleukin 1 beta.

19 uman articular cartilage, LfcinB antagonizes interleukin-1 beta (IL-1beta) and fibroblast growth fact

20 d secretion of the proinflammatory cytokines interleukin-1 beta (IL-1beta) and IL-18, which help cont

21 and clinical evidence reviewed here support interleukin-1 beta (IL-1beta) as both a local vascular a

22 Interleukin-1 beta (IL-1beta) is an inflammatory cytokin

23 Interleukin-1 beta (IL-1beta) is an inflammatory cytokin

24 GF), matrix metalloproteinase 9 (MMP-9), and interleukin-1 beta (IL-1beta) salivary biomarkers in the

25 inflammation-associated diseases by inducing interleukin-1 beta (IL-1beta) secretion.

26 matory interleukin-6 (IL-6) expression after interleukin-1 beta (IL-1beta) stimulation.

27 tor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1 beta (IL-1beta), and monocyte chemo attrac

28 Interferon-gamma (IFN-gamma), TNF-alpha, interleukin-1 beta (IL-1beta), fibroblast growth factor-

29 ia and induced the proinflammatory cytokine, interleukin-1 beta (IL-1beta).

30 , including aryl hydrocarbon receptor (Ahr), interleukin-1 beta (Il1b), estrogen receptor alpha (Esr1

31 n to activity levels through enhanced muscle interleukin-1 beta (IL1beta)/IL1 receptor signaling to g

32 normal tendon explants were stimulated with interleukin-1 beta and prostaglandin E(2).

33 e human cytokine proteins (interferon gamma, interleukin-1 beta, and tumor necrosis factor alpha) wer

34 ading depolarization such as upregulation of interleukin-1 beta, inducible nitric oxide synthase and

35 accumulation, and inhibited proinflammatory (interleukin-1 beta, tumor necrosis factor alpha, and F4/

36 e release of tumor necrosis factor-alpha and interleukin-1 beta, which are pro-inflammatory cytokines

37 after exposure to the inflammatory cytokine interleukin-1 beta.

38 juvants.In vitro, these compounds induced an interleukin 1-beta (IL-1beta) response in the macrophage

39 hfRPE was incubated with interleukin 1-beta (IL-1beta), interferon-gamma (IFNgamm

40 mRNA levels of cytokines interleukin 1-beta (IL1-beta) and tumor necrosis factor

41 ), monocyte chemotactic protein-1 (MCP1) and interleukin-1-beta (IL-1beta).

42 Interleukin 1 blockade is a viable option for therapy.

43 Interleukin-1 blockade has been utilized to treat system

44 ical and experimental evidence suggests that interleukin-1 blockade is effective against myocardial i

45 Interleukin-1 blockade might be more effective in combin

46 should be undertaken to confirm the role of interleukin-1 blockage.

47 own improvement following treatment with the interleukin-1 blocker anakinra.

48 Interleukin 33 (IL-33), a member of the Interleukin 1 cytokine family, is implicated in numerous

49 for activation of the potent proinflammatory interleukin-1 cytokine family.

50 The interleukin 1 family plays an important role in the immu

51 Caspase-1 mediates the production of interleukin-1 family cytokines (IL1FCs), leading to feve

52 tly modified interleukins, components of the interleukin-1 family were significantly up-regulated.

53 te immunity (most notably for members of the interleukin-1 family), which depend on the specific infl

54 lammatory mediators include cytokines of the interleukin-1 family, such as IL-1alpha and IL-1beta.

55 of the risk factors (RFs) smoking, diabetes, interleukin-1 genotype; or as LoR if no RFs.

56 f blockade of the key innate immune mediator interleukin-1 have been done.

57 The roles of the interleukin 1 (IL-1) and interleukin 18 pathways in host

58 cells and by mitigating the cytotoxicity of interleukin 1 (IL-1) and tumor necrosis factor-alpha (TN

59 randomized trial demonstrate that targeting interleukin 1 (IL-1) by topical application of an IL-1 a

60 Within the interleukin 1 (IL-1) cytokine family, IL-1 receptor acce

61 Here, we show that interleukin 1 (IL-1) enhances the capacity of weak vacci

62 Although interleukin 1 (IL-1) induces expression of the transcrip

63 Interleukin 1 (IL-1) is a major mediator for inflammatio

64 Interleukin 1 (IL-1) is an important mediator of innate

65 nt of bacterial clearance, deficiency in the interleukin 1 (IL-1) receptor led to a significant impai

66 Interleukin 1 (IL-1) receptor-associated kinase (IRAK)-M

67 Interleukin 1 (IL-1) receptor-associated kinases (IRAKs)

68 tokines such as tumor necrosis factor (TNF), interleukin 1 (IL-1), and interleukin 6 (IL-6).

69 N2 gene expression by ELF3 in the context of interleukin 1 (IL-1)-driven inflammatory responses in ch

70 temic inflammatory entity likely mediated by interleukin 1 (IL-1).

71 induced by proinflammatory cytokines such as interleukin 1 (IL-1).

72 olecule in inflammatory pathways involved in interleukin 1 (IL-1)/IL-18/Toll-like receptor signaling

73 Toll-like receptors (TLRs) and receptors for interleukin 1 (IL-1Rs) and to whole pathogens.

74 nce suggests that pro-inflammatory cytokines interleukin-1 (IL-1) and IL-18 show an age-dependent reg

75 Interleukin-1 (IL-1) and the IL-1 receptor (IL-1R) famil

76 We show here that stimulation with interleukin-1 (IL-1) and TNF induces a rapid and transie

77 of various proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha, th

78 h factor-beta, tumour necrosis factor (TNF), interleukin-1 (IL-1) and wnt family ligands.

79 to optimize combined anti-CD3 treatment plus interleukin-1 (IL-1) blockade to reverse new-onset disea

80 ry cytokines tumor necrosis factor (TNF) and interleukin-1 (IL-1) but not by growth factors platelet-

81 Here we demonstrate that interleukin-1 (IL-1) confers host resistance through the

82 duces inflammasome activation and release of interleukin-1 (IL-1) cytokines.

83 Here, we show that interleukin-1 (IL-1) enhances antigen-driven CD8 T cell

84 The interleukin-1 (IL-1) family cytokines are cytosolic prot

85 ed the inflammasome, leading to secretion of interleukin-1 (IL-1) family cytokines, pyroptosis, and c

86 cholesterol (25-HC) overproduce inflammatory interleukin-1 (IL-1) family cytokines.

87 Cytokines of the interleukin-1 (IL-1) family induce inflammation and regu

88 ead to caspase activation and release of the interleukin-1 (IL-1) family members, IL-1beta and IL-18.

89 which include Toll-like receptors (TLRs) and interleukin-1 (IL-1) family members, we found that MyD88

90 Toll-like and interleukin-1 (IL-1) family receptors recognize microbia

91 Interleukin-1 (IL-1) gene polymorphisms have been associ

92 The cytokine interleukin-1 (IL-1) has two main pro-inflammatory forms

93 Interleukin-1 (IL-1) is a central mediator of innate imm

94 Interleukin-1 (IL-1) is a large cytokine family closely

95 Interleukin-1 (IL-1) is implicated in numerous pathologi

96 sion of the pivotal proinflammatory cytokine interleukin-1 (IL-1) is increased in CML bone marrow.

97 Interleukin-1 (IL-1) mediates diverse neurophysiological

98 Inflammatory cytokine interleukin-1 (IL-1) performs multiple functions in the

99 generation as well as caspase-8 activity and interleukin-1 (IL-1) production.

100 Overexpression of several markers such as interleukin-1 (IL-1) receptor accessory protein (IL1RAP)

101 esponding normal cells, express a functional interleukin-1 (IL-1) receptor complex and respond with N

102 downstream of Toll-like receptors (TLRs) and interleukin-1 (IL-1) receptor family members.

103 g K63-linked polyubiquitination of Pelle, an interleukin-1 (IL-1) receptor-associated kinase homolog

104 ic brain injury, and to evaluate the role of interleukin-1 (IL-1) signaling as a target for pharmacol

105 Interleukin-1 (IL-1) signaling in fibroblasts is mediate

106 s recently been identified as a regulator of interleukin-1 (IL-1) signaling, but its roles in regulat

107 ase (IKK)/NF-kappaB signaling in response to interleukin-1 (IL-1) stimulation.

108 DCs are defined by their ability to release interleukin-1 (IL-1) while maintaining cell viability, e

109 Interleukin-1 (IL-1), a potent inflammatory cytokine in

110 Interleukin-1 (IL-1), an important proinflammatory cytok

111 Consistent with in vitro experiments, interleukin-1 (IL-1)-dependent autoantibody-mediated art

112 Interleukin-1 (IL-1)-induced activation of the mTOR kina

113 Pathogenic variants in two interleukin-1 (IL-1)-regulating genes, NLRP3 and IL1RN,

114 ECM) degradation, cells were co-treated with interleukin-1 (IL-1).

115 tochemically to evaluate the distribution of interleukin-1 (IL-1).

116 r molecule that mediates the TNFR family and interleukin-1 (IL-1)/Toll-like receptor (TLR) signaling

117 ls), and measured levels of cytokines of the interleukin 1 (IL1) family (IL1alpha, IL1beta, IL1ra, an

118 r toll-like receptors and also implicated in interleukin-1 (Il1) signaling, in a murine model of exte

119 ption of IFNB1 but not of the genes encoding interleukin-1 (IL1), interleukin-6 (IL6), or tumor necro

120 g to a role for the proinflammatory cytokine interleukin-1 in myocardial inflammation and contractile

121 Knockdown of each class I HDAC diminished interleukin-1-induced MMP13 expression.

122 Interleukin-1 inhibition causes a greater improvement in

123 on of cardiac function responded promptly to interleukin-1 inhibition.

124 Inhibition of interleukin 1 is a promising treatment strategy.

125 Interleukin-1 is a key proinflammatory cytokine in FMF.

126 Interleukin-1 is an important mediator of cartilage dest

127 Interleukin-1 is pivotal in the pathogenesis of systemic

128 The activity of interleukin-1 is regulated by multimolecular protein com

129 l of the M1-pUb chains formed in response to interleukin-1, or the Toll-Like Receptors 1/2 agonist Pa

130 Here we show that hyperactivation of the interleukin 1 pathway, through either ablation of the in

131 cytokines (such as tumor necrosis factor and interleukin-1), reactive oxygen species (ROS), pathogens

132 activation is mediated through TRAF6 in the interleukin 1 receptor (IL-1R) and toll-like receptor (T

133 h their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathwa

134 LLIP) regulates Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling against mycobac

135 ive influenza A virus, signaling through the interleukin 1 receptor (IL-1R) was required for producti

136 DA-5), as well as cytokine receptors such as interleukin 1 receptor (IL-1R), have been implicated in

137 Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR), a negative regulator of

138 n primary response gene 88 (MyD88)- and Toll-interleukin 1 receptor (TIR) domain-containing adaptor i

139 Here, we describe a Toll/interleukin 1 receptor (TIR) domain-containing protein (

140 SENSITIVE 3 (CHS3) encodes an atypical Toll/Interleukin 1 Receptor (TIR)-type NLR protein with an ad

141 or the upstream mediator of its expression, interleukin 1 receptor 1.

142 in 1 pathway, through either ablation of the interleukin 1 receptor 8 (IL-1R8, also known as SIGIRR o

143 The interleukin 1 receptor accessory protein (IL1RAP; IL1R3)

144 IRAK-4 and MyD88 deficiencies impair interleukin 1 receptor and Toll-like receptor (TLR) sign

145 h rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and

146 Serum interleukin 1 receptor antagonist (IL-1RA) levels were e

147 centrations of interleukin 1beta (IL-1beta), interleukin 1 receptor antagonist (IL-1Ra), and granuloc

148 lymorphisms of interleukin 1 beta (IL1B) and interleukin 1 receptor antagonist (IL1RA) genes for asso

149 nd, even more importantly, anti-inflammatory interleukin 1 receptor antagonist (IL1Rn).

150 d P = .00005 for IMI, by the log-rank test), interleukin 1 receptor antagonist (IL1RN; rs419598; P =

151 Finally, inclusion of interleukin 1 receptor antagonist (Kineret(R)) in the ad

152 nduced protein [IP-10]) and proinflammatory (interleukin 1 receptor antagonist [IL-1RA], IL-6) cytoki

153 sis revealed an inverse relationship between interleukin 1 receptor antagonist and colony-stimulating

154 itric oxide synthase, interleukin-1beta, and interleukin 1 receptor antagonist but not transforming g

155 tory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease i

156 Potential immune markers, including interleukin 1 receptor antagonist, interferon gamma-indu

157 le nucleotide polymorphism A471T in the Toll-interleukin 1 receptor domain (TIR) of the IL-1Rrp2 that

158 ctivate downstream signaling via TIRAP (Toll-interleukin 1 receptor domain containing adaptor protein

159 ne spanning region and an intracellular Toll/Interleukin 1 receptor domain which invokes signal trans

160 rimary response protein 88 (MyD88), and Toll interleukin 1 receptor domain-containing adaptor protein

161 n primary murine macrophages, dependent upon interleukin 1 receptor-associated kinase (IRAK-1).

162 mammals and overlaps with the 5' UTR of the interleukin 1 receptor-associated kinase (IRAK1) gene.

163 This included a Phe196Ser change in the interleukin 1 receptor-associated kinase 1 (IRAK1).

164 ma infection than wild-type, Dectin-1-/-, or interleukin 1 receptor-deficient (IL-1R-/-) mice.

165 ivates many immune cell types expressing the interleukin 1 receptor-like 1 (IL1RL1) receptor ST2, inc

166 hil C-C chemokine receptor type 3 (CCR3) and interleukin 1 receptor-like 1 (ST2) in vivo.

167 members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) families transduce signal

168 ), a negative regulator of the Toll-like and interleukin-1 receptor (IL-1R) signaling pathways, contr

169 e expression of the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily, IL-1beta pro

170 Surprisingly, the interleukin-1 receptor (IL-1R) was required for an AEC c

171 ting microglia expressed high amounts of the interleukin-1 receptor (IL-1R), and treatment with an IL

172 c expression of toll-like receptor 4 (TLR4), interleukin-1 receptor (IL-1R), or interferon-gamma rece

173 Interleukin-1 receptor (IL-1R)-associated kinase (IRAK)

174 We identified interleukin-1 receptor (IL-1R)-associated kinase 1 (IRAK

175 fied nearly two decades ago as a mediator of interleukin-1 receptor (IL-1R)-mediated activation of NF

176 ponses are controlled through members of the interleukin-1 receptor (IL-1R)/Toll-like receptor superf

177 Herein, by using the toll/interleukin-1 receptor (TIR) domain homologous C-termina

178 rly Leu265Pro (L265P), within the MyD88 Toll/interleukin-1 receptor (TIR) domain sustain lymphoma cel

179 e-rich repeat (NLR) protein with a Toll-like interleukin-1 receptor (TIR) domain, which mediates XopQ

180 Toll/interleukin-1 receptor (TIR) domain-containing adapter p

181 lipopolysaccharide, this is a delayed, Toll/interleukin-1 receptor (TIR) domain-containing adapter-i

182 esponses by targeted degradation of the Toll/interleukin-1 receptor (TIR) domain-containing adaptor p

183 L6 is a Toll/interleukin-1 receptor (TIR) domain-containing NLR from

184 ults in dimerization of their cytosolic Toll/interleukin-1 receptor (TIR) domains and recruitment of

185 Toll-like receptors (TLRs), cytoplasmic Toll/interleukin-1 receptor (TIR) domains of the receptors un

186 aling adapter protein interactions with Toll/Interleukin-1 Receptor (TIR) domains present in sensory

187 Analysis of Toll/interleukin-1 receptor (TIR) sequences indicated that th

188 structures of MAL revealed a nontypical Toll/interleukin-1 receptor (TIR)-domain fold stabilized by t

189 equires the P loops of each protein and Toll/interleukin-1 receptor (TIR)-domain-mediated heteromeric

190 In the amygdala significant up-regulation of interleukin-1 receptor 1 (IL1r1), interleukin-4 receptor

191 Interleukin-1 receptor 8 (IL-1R8, also known as single i

192 D88(-/-), MyD88/TLR adaptor molecule 1(-/-), interleukin-1 receptor [IL-1R1](-/-), and interleukin (I

193 Interleukin-1 receptor accessory protein (IL1RAP; IL1R3)

194 Mutations and deletions of the interleukin-1 receptor accessory protein like 1 (IL1RAPL

195 the X-linked intellectual disability protein interleukin-1 receptor accessory protein like 1 (IL1RAPL

196 E) epsilon4 status was identified in IL1RAP (interleukin-1 receptor accessory protein; rs12053868-G;

197 ndings broaden our understanding of how Toll/interleukin-1 receptor adaptor proteins may participate

198 TLR2 and TLR4 signal via the Toll/interleukin-1 receptor adaptors MyD88 and MAL, leading t

199 Tear concentrations increased for interleukin-1 receptor antagonist (16 557.1 +/- 4047.8 v

200 multifocal osteomyelitis, deficiency of the interleukin-1 receptor antagonist (DIRA), Majeed syndrom

201 lute partial correlation coefficients >0.40: Interleukin-1 receptor antagonist (IL-1Ra) and IL-8.

202 We therefore examined the influence of interleukin-1 receptor antagonist (IL-1Ra) on MCL healin

203 e investigated whether the anti-inflammatory interleukin-1 receptor antagonist (IL-1Ra) prevents muri

204 itors enhance the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) secretion in

205 production of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA) that could be

206 Notably, the hepatic expression of interleukin-1 receptor antagonist (IL-1ra) was suppresse

207 necrosis factor (TNF) receptor-2 (TNFR2) and interleukin-1 receptor antagonist (IL-1ra) were fused to

208 The endogenous interleukin-1 receptor antagonist (IL-1Ra), an inflammat

209 culating levels of C-reactive protein (CRP), interleukin-1 receptor antagonist (IL-1Ra), and soluble

210 otype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA).

211 at a single intracisternal administration of interleukin-1 receptor antagonist (IL-1RA; 112 mug) at t

212 sma levels of neopterin (P<;0.0001), soluble interleukin-1 receptor antagonist (P<;0.0001), IL-8 (P=0

213 D and confirmed six proteins (leptin, renin, interleukin-1 receptor antagonist [IL-1ra], hepatocyte g

214 The biologic agents interleukin-1 receptor antagonist and antitumor necrosis

215 3), and antiinflammatory markers (increased interleukin-1 receptor antagonist and lower monocyte and

216 py efficacy stemmed from the upregulation of interleukin-1 receptor antagonist and suppression of MDS

217 rosis factor-alpha and interleukin-6 and the interleukin-1 receptor antagonist compared with control

218 l activation by minocycline or by transgenic interleukin-1 receptor antagonist overexpression rescued

219 in plasma interleukin-8, interleukin-10, and interleukin-1 receptor antagonist posttransfusion compar

220 akinra is a recombinant version of the human interleukin-1 receptor antagonist used to treat autoinfl

221 nd 2, C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist were measured in 233 i

222 or necrosis factor-alpha, interleukin-6, and interleukin-1 receptor antagonist), their mRNA expressio

223 associated with augmented concentrations of interleukin-1 receptor antagonist, a key anti-inflammato

224 interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved beta-cell fu

225 We investigated the effects of anakinra, an interleukin-1 receptor antagonist, on coronary and left

226 Component 1 (interleukin-1 receptor antagonist, QA, and kynurenine) w

227 ed growth factor receptors, and anakinra, an interleukin-1 receptor antagonist, respectively, increas

228 ly attenuated by treatment with anakinra, an interleukin-1 receptor antagonist.

229 eating glutathione peroxidase 1 mice with an interleukin-1 receptor antagonist.

230 a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using

231 In this subgroup analysis, interleukin-1 receptor blockade was associated with sign

232 ctivation syndrome features may benefit from interleukin-1 receptor blockade.

233 entricular assist device, treatment with the interleukin-1 receptor blocking agent anakinra 100 mg/d

234 nt with fulminant viral myocarditis with the interleukin-1 receptor blocking agent anakinra.

235 ndicating that the Toll-6 receptor, the Toll/interleukin-1 receptor domain adaptor dSARM, and FoxO fu

236 Pharmacologic and genetic disruption of Toll/interleukin-1 receptor domain-containing adapter inducin

237 The TLR adaptor Toll/interleukin-1 receptor domain-containing adapter-inducin

238 cell line Mono Mac 6, induction of the Toll-interleukin-1 receptor domain-containing adaptor-inducin

239 production of ETs by S cells requires a Toll/Interleukin-1 receptor domain-containing protein TirA an

240 Four biomarkers, soluble form of ST2 (an interleukin-1 receptor family member), galectin-3, matri

241 The interleukin-1 receptor I (IL-1RI) is critical for host r

242 chemoattractant protein-1, resistin, soluble interleukin-1 receptor I, soluble interleukin-2 receptor

243 -/-)), caspase-1 knockout (Casp-1(-/-)), and interleukin-1 receptor knockout (IL-1R(-/-)) mice treate

244 because deletion of Nlrp3, caspase-1 and the interleukin-1 receptor markedly protects against rheumat

245 all genes predicted to contain either a Toll/interleukin-1 receptor or nucleotide-binding site domain

246 In Toll-like receptor and interleukin-1 receptor signaling pathways, the kinase IR

247 mon adaptor for toll-like receptor (TLR) and Interleukin-1 receptor signaling, are critical for radio

248 rotein that mediates Toll-like receptors and interleukin-1 receptor signaling.

249 ucially relies on the Nlrp3 inflammasome and interleukin-1 receptor signalling.

250 d the role of toll-like receptors (TLRs) and interleukin-1 receptor type 1 (IL-1R1) in S. marcescens-

251 nization, we show that mice deficient in the interleukin-1 receptor type 1 (Il1r1(-/-)) have reduced

252 y protein (IL1RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregul

253 Interleukin-1 receptor type 2 (IL1R2) acts as a decoy re

254 Interleukin-1 receptor type I knockout mice, which displ

255 r the SAM (sterile alpha motif) or TIR (Toll-interleukin-1 receptor) domains abolishes the ability of

256 00 [UL = unique long]) and host-genes (e.g., interleukin-1 receptor, IRF1).

257 signalling (tumour necrosis factor receptor/interleukin-1 receptor, TNFR/IL-1R in mammals) is indisp

258 The 28-kDa form of IL-1beta cannot activate interleukin-1 receptor-1 (IL1R1) to signal inflammatory

259 013) describe a molecular system implicating interleukin-1 receptor-2 (IL-1R2) as a principal cytosol

260 to caspase proteolytic activity that cleaves interleukin-1 receptor-2, allowing IL-1alpha dissociatio

261 n assays show that IL-1alpha associates with interleukin-1 receptor-2, and this association is decrea

262 pathway involving the MyD88 adapter and the interleukin-1 receptor-associated kinase (IRAK) complex.

263 id differentiation primary response (MyD88), interleukin-1 receptor-associated kinase 1 (IRAK-1), and

264 Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is ov

265 Inhibition of BTK or interleukin-1 receptor-associated kinase 1 and 4 (IRAK-1

266 use of TMP with Bruton's tyrosine kinase or interleukin-1 receptor-associated kinase 1 and 4 inhibit

267 rvival pathway, leading to downregulation of interleukin-1 receptor-associated kinase 1.

268 rvival pathway, leading to downregulation of interleukin-1 receptor-associated kinase 1.

269 ed NFkappaB activation, via interaction with interleukin-1 receptor-associated kinase 2 (IRAK2).

270 onse was reversed in the patient, but not in interleukin-1 receptor-associated kinase 4 (IRAK-4)-defi

271 Interleukin-1 receptor-associated kinase 4 (IRAK4) plays

272 ying very rare loss-of-function mutations in interleukin-1 receptor-associated kinase 4 (IRAK4), a cr

273 Interleukin-1 receptor-associated kinase 4 (IRAK4), a ma

274 diminished degradation and interaction with interleukin-1 receptor-associated kinase 4 (IRAK4).

275 Abs induced activation of TLR4 and triggered interleukin-1 receptor-associated kinase phosphorylation

276 main containing adaptor protein)-MyD88-IRAK (interleukin-1 receptor-associated kinase)1/4-TRAF6 (TNF

277 o-1 actions were likely to be independent of interleukin-1 receptor-associated kinase-1 (IRAK-1) regu

278 Within innate immune signaling pathways, interleukin-1 receptor-associated kinases (IRAKs) fulfil

279 its DD and TIR domain and interacts with the interleukin-1 receptor-associated kinases (IRAKs) to for

280 e deficient in the TLR adaptor proteins Toll/interleukin-1 receptor-domain-containing adaptor protein

281 dipocyte differentiation, whereas Got2, Cpq, interleukin-1 receptor-like 1/ST2-IL-33, Sparc, and Lgal

282 uide cleavage of transcripts of the Toll and Interleukin-1 receptor-NB-LRR immune receptor N from tob

283 ream of multiple Toll-like receptors and the interleukin-1 receptor.

284 ner dependent on signaling downstream of the interleukin-1 receptor.

285 We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhi

286 Toll/interleukin-1-receptor domain containing adaptor protein

287 Interleukin-1-receptor-like-1 (IL1RL1 or ST2) is a well-

288 in that links toll-like receptors (TLRs) and Interleukin-1 receptors (IL-1Rs) with downstream signali

289 evoked by the Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs).

290 s the key signaling adapter of Toll-like and interleukin-1 receptors.

291 Both lipids induce caspase-11-dependent interleukin-1 release, but only LPS induces pyroptosis.

292 mpaired nuclear factor-kappaB activation and interleukin-1 release.

293 d disabling conditions mediated by increased interleukin-1 secretion.

294 terleukin 1beta, suggesting a disturbance in interleukin 1 signaling.

295 he stability of wild-type MLL in response to interleukin-1 signaling.

296 ture of systemic lupus erythematosus and the interleukin-1 signature in systemic onset juvenile idiop

297 he formation of M1-pUb chains in response to interleukin-1, that the formation of K63-pUb chains is a

298 f clinical response of sJIA and CAPS to anti-interleukin 1 therapies prompted a comparison at the bio

299 kine, that activates multiple members of the interleukin-1/Toll-like receptor (TLR) family associated

300 Fadd and Tnfsf9) and inflammatory (for, eg, interleukin 1, tumor necrosis factor alpha, chemokines,